Literature DB >> 23157406

Metabolomics and ischaemic heart disease.

Aliki A Rasmiena1, Theodore W Ng, Peter J Meikle.   

Abstract

Ischaemic heart disease accounts for nearly half of the global cardiovascular disease burden. Aetiologies relating to heart disease are complex, but dyslipidaemia, oxidative stress and inflammation are cardinal features. Despite preventative measures and advancements in treatment regimens with lipid-lowering agents, the high prevalence of heart disease and the residual risk of recurrent events continue to be a significant burden to the health sector and to the affected individuals and their families. The development of improved risk models for the early detection and prevention of cardiovascular events in addition to new therapeutic strategies to address this residual risk are required if we are to continue to make inroads into this most prevalent of diseases. Metabolomics and lipidomics are modern disciplines that characterize the metabolite and lipid complement respectively, of a given system. Their application to ischaemic heart disease has demonstrated utilities in population profiling, identification of multivariate biomarkers and in monitoring of therapeutic response, as well as in basic mechanistic studies. Although advances in magnetic resonance and mass spectrometry technologies have given rise to the fields of metabolomics and lipidomics, the plethora of data generated presents challenges requiring specific statistical and bioinformatics applications, together with appropriate study designs. Nonetheless, the predictive and re-classification capacity of individuals with various degrees of risk by the plasma lipidome has recently been demonstrated. In the present review, we summarize evidence derived exclusively by metabolomic and lipidomic studies in the context of ischaemic heart disease. We consider the potential role of plasma lipid profiling in assessing heart disease risk and therapeutic responses, and explore the potential mechanisms. Finally, we highlight where metabolomic studies together with complementary -omic disciplines may make further inroads into the understanding, detection and treatment of ischaemic heart disease.

Entities:  

Mesh:

Year:  2013        PMID: 23157406     DOI: 10.1042/CS20120268

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  17 in total

1.  Human plasma lipidome is pleiotropically associated with cardiovascular risk factors and death.

Authors:  Claire Bellis; Hemant Kulkarni; Manju Mamtani; Jack W Kent; Gerard Wong; Jacquelyn M Weir; Christopher K Barlow; Vincent Diego; Marcio Almeida; Thomas D Dyer; Harald H H Göring; Laura Almasy; Michael C Mahaney; Anthony G Comuzzie; Sarah Williams-Blangero; Peter J Meikle; John Blangero; Joanne E Curran
Journal:  Circ Cardiovasc Genet       Date:  2014-11-02

2.  Untargeted metabolomic analysis of coronary artery disease patients with diastolic dysfunction show disturbed oxidative pathway.

Authors:  Tamkeen Fatima; Satwat Hashmi; Ayesha Iqbal; Amna Jabbar Siddiqui; Shahid A Sami; Najeeb Basir; Syeda Saira Bokhari; Hasanat Sharif; Syed Ghulam Musharraf
Journal:  Metabolomics       Date:  2019-06-24       Impact factor: 4.290

3.  Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families.

Authors:  Hemant Kulkarni; Peter J Meikle; Manju Mamtani; Jacquelyn M Weir; Marcio Almeida; Vincent Diego; Juan Manuel Peralta; Christopher K Barlow; Claire Bellis; Thomas D Dyer; Laura Almasy; Michael C Mahaney; Anthony G Comuzzie; Harald H H Göring; Joanne E Curran; John Blangero
Journal:  J Lipid Res       Date:  2014-03-13       Impact factor: 5.922

4.  Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.

Authors:  Tomasz Dawiskiba; Stanisław Deja; Agata Mulak; Adam Ząbek; Ewa Jawień; Dorota Pawełka; Mirosław Banasik; Agnieszka Mastalerz-Migas; Waldemar Balcerzak; Krzysztof Kaliszewski; Jan Skóra; Piotr Barć; Krzysztof Korta; Kornel Pormańczuk; Przemyslaw Szyber; Adam Litarski; Piotr Młynarz
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 5.  Personalized nutrition and obesity.

Authors:  Lu Qi
Journal:  Ann Med       Date:  2014-04-10       Impact factor: 4.709

Review 6.  Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences.

Authors:  Kui Yang; Xianlin Han
Journal:  Trends Biochem Sci       Date:  2016-09-20       Impact factor: 13.807

7.  Aliphatic chain length by isotropic mixing (ALCHIM): determining composition of complex lipid samples by ¹H NMR spectroscopy.

Authors:  Joseph R Sachleben; Ruiyang Yi; Paul A Volden; Suzanne D Conzen
Journal:  J Biomol NMR       Date:  2014-05-15       Impact factor: 2.835

Review 8.  Lipidomics in vascular health: current perspectives.

Authors:  Genovefa Kolovou; Vana Kolovou; Sophie Mavrogeni
Journal:  Vasc Health Risk Manag       Date:  2015-06-12

Review 9.  Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery.

Authors:  Douglas B Kell; Royston Goodacre
Journal:  Drug Discov Today       Date:  2013-07-26       Impact factor: 7.851

10.  Plasma metabonomics study on Chinese medicine syndrome evolution of heart failure rats caused by LAD ligation.

Authors:  Qi Qiu; Chun Li; Yong Wang; Cheng Xiao; Yu Li; Yang Lin; Wei Wang
Journal:  BMC Complement Altern Med       Date:  2014-07-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.